Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...
Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID-19 and Ebola -- while also minimizing side effects and reducing the odds of ...
The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic-;an effective antiviral that has since successfully treated millions.